NCT00058994

Brief Summary

The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Mar 2003

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2003

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 15, 2003

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 16, 2003

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2006

Completed
Last Updated

November 29, 2012

Status Verified

August 1, 2008

Enrollment Period

3.7 years

First QC Date

April 15, 2003

Last Update Submit

November 28, 2012

Conditions

Macular DegenerationMaculopathy, Age-Related

Keywords

AMDanecortave acetatewet AMDage-related macular degenerationMacular DegenerationMaculopathy, Age-RelatedAge-Related MaculopathiesAge-Related MaculopathyMaculopathies, Age-Related

Interventions

anecortave acetateDRUG

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Patients at least 50 years of age, of any race, and either sex with a clinical diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Study Sites (1)

South America

Fort Worth, Texas, United States

Location

MeSH Terms

Conditions

Macular Degeneration

Interventions

anecortave acetate

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Officials

  • Alcon Investigators

    Alcon Research

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2003

First Posted

April 16, 2003

Study Start

March 1, 2003

Primary Completion

November 1, 2006

Study Completion

November 1, 2006

Last Updated

November 29, 2012

Record last verified: 2008-08

Locations

US(1)